Drugs Made In America Acquisition (DMIIR) Accumulated Expenses (2024 - 2025)
Drugs Made In America Acquisition (DMIIR) reported Accumulated Expenses of $88343.0 for Q4 2025, up 1786.46% year-over-year from $4683.0 in Q4 2024, and up 1411.95% on a QoQ basis from $5843.0 in Q3 2025.
Drugs Made In America Acquisition (DMIIR) has 2 years of Accumulated Expenses data on file, last reported at $88343.0 in Q4 2025.
- Quarterly Accumulated Expenses rose 1786.46% year-over-year to $88343.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $88343.0 (up 1786.46% YoY) and the FY2025 annual result came in at $88343.0, up 1786.46% from the prior year.
- Accumulated Expenses climbed to $88343.0 in Q4 2025 per DMIIR's latest filing, from $5843.0 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $88343.0 in Q4 2025 and bottomed at $4683.0 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | EQV Ventures Acquisition | 477.69 Mn | 477.69 Mn | - |
| 2 | Berto Acquisition | 316.66 Mn | 316.66 Mn | - |
| 3 | Centurion Acquisition | 311.94 Mn | 311.94 Mn | - |
| 4 | Churchill Capital Corp IX | 311.36 Mn | 311.36 Mn | - |
| 5 | Agriculture & Natural Solutions Acquisition | 301.94 Mn | 301.94 Mn | - |
| 6 | Siddhi Acquisition Corp (Cayman Islands) | 286.76 Mn | 286.76 Mn | - |
| 7 | Bold Eagle Acquisition | 276.06 Mn | 276.06 Mn | - |
| 8 | Cartesian Growth Corp III | 270.68 Mn | 270.68 Mn | - |
| 9 | Oyster Enterprises II Acquisition | 266.84 Mn | 266.84 Mn | - |
| 10 | Drugs Made In America Acquisition | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 88,343.00 |
| Sep 30, 2025 | 5,843.00 |
| Dec 31, 2024 | 4,683.00 |